ESTRO 2022 - Abstract Book

S1148

Abstract book

ESTRO 2022

PO-1353 SBRT for gynecological oligometastases: mono-institutional report of toxicity and clinical outcomes

F. Cuccia 1 , E. Pastorello 1 , C. Vitale 1 , V. Figlia 1 , N. Giaj-Levra 1 , L. Nicosia 1 , F. Ricchetti 1 , M. Rigo 1 , R. Mazzola 1 , M. Ceccaroni 2 , R. Ruggieri 1 , F. Alongi 1 1 IRCCS Sacro Cuore Don Calabria, Advanced Radiation Oncology Department, Negrar di Valpolicella, Italy; 2 IRCCS Sacro Cuore Don Calabria, Gynecology Unit, Negrar di Valpolicella, Italy Purpose or Objective Background : The use of stereotactic radiotherapy (SBRT) for oligometastases is supported by several studies, despite being quite unexplored in the setting of gynecological malignancies. This study reports a preliminary evaluation of clinical outcomes in a cohort of 40 patients with oligometastatic gynecological cancers. Materials and Methods Methods : Radiotherapy was delivered in 3-10 fractions with VMAT-IGRT technique. Toxicity was retrospectively collected according to CTCAE v4.0. Univariate and multivariate analyses were performed for assessing any potential predictive factor for clinical outcomes. Results Results: A total of 63 oligometastases were treated from December 2014 to February 2021. Median age was 63 years (range 30-89). Most frequent primary tumors were ovarian cancer in 42.5% and endometrium cancer in 42.5%. With a median follow-up of 27 months (range 6-69), no local failures were observed, our progression-free survival rates were 43.6% and 23% at one and 2 years, respectively. Sixteen patients developed a sequential oligometastatic disease, candidate to a further SBRT course, with a second progression-free survival (PFS2) of 13 months (range 2–27); nonetheless, this did not lead to a survival advantage, when compared to patients who developed immediate polymetastatic spread (p= 0.47). 1 and 2-year overall survival rates were both 70%, with only one patient dead by disease. No acute or late G ≥ 2 adverse events were observed. Conclusion Conclusions : SBRT for oligometastatic gynecological malignancies resulted in promising results in terms of clinical outcomes, with excellent local control and no evidence of severe toxicity. Prospective studies to further investigate the role of this option in the management of gynecological malignancies are advocated. D. Pezzulla 1 , G. Macchia 2 , M. Ferro 2,2 , S. Cilla 3 , M. Buwenge 4,5 , M. Boccardi 2 , C. Romano 3 , S. Cammelli 6 , P. Bonome 2 , V. Valentini 7,8 , A.G. Morganti 9,10 , F. Deodato 2,11 1 Gemelli Molise Hospital – Università Cattolica del Sacro Cuore, Radiation Oncology Unit, Campobasso, Italy; 2 Gemelli Molise Hospital – Università Cattolica del Sacro Cuore, Radiation Oncology Unit, Campobasso, Italy; 3 Gemelli Molise Hospital – Università Cattolica del Sacro Cuore, Medical Physics Unit, Campobasso, Italy; 4 IRCCS Azienda Ospedaliero- Universitaria Di Bologna, Radiation Oncology, Bologna, Italy; 5 DIMES, Alma Mater Studiorum Bologna University, Department of Experimental, Diagnostic, and Specialty Medicine , Bologna, Italy; 6 IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Radiation Oncology, Bologna, Italy; 7 Fondazione Policlinico Universitario A Gemelli IRCCS, UOC di Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia , Roma, Italy; 8 Università Cattolica del Sacro Cuore, Istituto di Radiologia , Roma, Italy; 9 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Radiation Oncology, Bologna, Italy; 10 DIMES, Alma Mater Studiorum Bologna University, Department of Experimental, Diagnostic, and Specialty Medicine, Bologna, Italy; 11 Università Cattolica del Sacro Cuore, Istituto di Radiologia, Roma, Italy Purpose or Objective To report the toxicity profile, local control (LC) rate and Quality of life (QoL) data in patients suffering from recurrent gynaecological cancer undergone stereobody radiotherapy (SBRT) retreatment. Materials and Methods Data from patient folders were retrospectively collected, focusing in particular on primary, previous systemic therapies and previous radiotherapy treatments. Concerning SBRT, the total dose (5 daily fractions) was delivered with a linear accelerator using VMAT technique. Acute and late toxicities were assessed by the RTOG/EORTC scales. The quality of life (QoL) was evaluated according to the CLAS 1 (fatigue), 2 (energy level), 3 (daily activities) scales. Results 23 patients (median age 67 years, range 48-80) bearing 27 lesions were treated from December 2006 to August 2021. The majority of patients had ovarian (39.1%) and endometrial cancer (39.1%) as the primary tumor. The most used SBRT schedules were 30 Gy (37.0%), 35 Gy (29.6%) and 40 Gy (29.0%). More details are shown in Table 1. PO-1354 Stereotactic body re-irradiation for gynaecological cancer: outcomes and toxicities